22 results
Bevespi aerosphere (glycopyrrolate and formoterol fumarate)
(Glycopyrrolate and formoterol fumarate)AstraZeneca Pharmaceuticals LP
Usage: BEVESPI AEROSPHERE is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is not intended for acute bronchospasm relief or asthma treatment.
Brilinta (ticagrelor)
(Ticagrelor)AstraZeneca Pharmaceuticals LP
Usage: BRILINTA is indicated for reducing the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. It is also used to lower the risk of a first myocardial infarction or stroke in high-risk patients with coronary artery disease, and to reduce stroke risk in patients with acute ischemic stroke or high-risk transient ischemic attack.
Bydureon bcise (exenatide)
(exenatide)AstraZeneca Pharmaceuticals LP
Usage: BYDUREON BCISE is indicated for improving glycemic control in adults and pediatric patients aged 10 and older with type 2 diabetes, as an adjunct to diet and exercise. It is not recommended for first-line therapy, type 1 diabetes, or patients with a history of pancreatitis.
Calquence (acalabrutinib)
(Acalabrutinib)AstraZeneca Pharmaceuticals LP
Usage: CALQUENCE is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) after prior therapy, and for those with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Approval for MCL is based on an accelerated approval process contingent on further clinical benefit verification.
Calquence (acalabrutinib)
(acalabrutinib)AstraZeneca Pharmaceuticals LP
Usage: CALQUENCE is indicated for adult patients with previously untreated or treated mantle cell lymphoma (MCL), those ineligible for autologous stem cell transplantation, and patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Crestor (rosuvastatin calcium)
(Rosuvastatin calcium)AstraZeneca Pharmaceuticals LP
Usage: CRESTOR is indicated to reduce cardiovascular risk in adults without coronary heart disease and to lower LDL cholesterol in various conditions, including primary hyperlipidemia, heterozygous and homozygous familial hypercholesterolemia, primary dysbetalipoproteinemia, and hypertriglyceridemia, as an adjunct to diet and other therapies.
Daliresp (roflumilast)
(roflumilast)AstraZeneca Pharmaceuticals LP
Usage: DALIRESP® is indicated for reducing the risk of COPD exacerbations in patients with severe COPD and chronic bronchitis who have a history of exacerbations. It is not a bronchodilator and is not suitable for acute bronchospasm relief. The initial dose is 250 mcg for the first 4 weeks.
Duaklir pressair (aclidinium bromide and formoterol fumarate)
(aclidinium bromide and formoterol fumarate)AstraZeneca Pharmaceuticals LP
Usage: DUAKLIR PRESSAIR is prescribed for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It combines aclidinium bromide, an anticholinergic, with formoterol fumarate, a long-acting beta-agonist (LABA). It is not intended for acute bronchospasm relief or asthma treatment.
Farxiga (dapagliflozin)
(DAPAGLIFLOZIN)AstraZeneca Pharmaceuticals LP
Usage: FARXIGA (dapagliflozin) is indicated for reducing the risk of kidney disease progression, cardiovascular death, hospitalization for heart failure in adults with heart disease, and improving glycemic control in type 2 diabetes patients aged 10 and older, alongside diet and exercise. Not recommended for type 1 diabetes or eGFR <45 mL/min.
Fasenra (benralizumab)
(Benralizumab)AstraZeneca Pharmaceuticals LP
Usage: FASENRA is indicated for add-on maintenance treatment of severe asthma in patients aged 6 and older with an eosinophilic phenotype, and for adults with eosinophilic granulomatosis with polyangiitis (EGPA). It is not for acute bronchospasm relief.